Mon, August 10, 2020

Matthew Harrison Maintained (SRPT) at Buy with Increased Target to $182 on, Aug 10th, 2020

Matthew Harrison of Morgan Stanley, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Buy with Increased Target from $172 to $182 on, Aug 10th, 2020.

Matthew has made no other calls on SRPT in the last 4 months.



There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Matthew's Rating of Hold.



This is the rating of the analyst that currently disagrees with Matthew


  • Tazeen Ahmad of "B of A Securities" Maintained at Strong Buy and Held Target at $180 on, Wednesday, June 10th, 2020